Matinas BioPharma Holdings, Inc. (MTNB)
- Previous Close
0.1818 - Open
0.1802 - Bid --
- Ask --
- Day's Range
0.1750 - 0.1860 - 52 Week Range
0.1100 - 0.8900 - Volume
681,396 - Avg. Volume
1,570,648 - Market Cap (intraday)
45.523M - Beta (5Y Monthly) 1.55
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.00
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
www.matinasbiopharma.comRecent News: MTNB
Performance Overview: MTNB
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MTNB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MTNB
Valuation Measures
Market Cap
45.52M
Enterprise Value
35.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
35.98
Price/Book (mrq)
2.37
Enterprise Value/Revenue
32.23
Enterprise Value/EBITDA
-1.55
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.49%
Return on Equity (ttm)
-82.11%
Revenue (ttm)
1.1M
Net Income Avi to Common (ttm)
-22.94M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
13.76M
Total Debt/Equity (mrq)
18.48%
Levered Free Cash Flow (ttm)
-6.85M